A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung Cancer

Published:2012-10-26 Issue:1 Volume:11 Page:27-43
ISSN:1175-5652
Container-title:Applied Health Economics and Health Policy
language:en
Short-container-title:Appl Health Econ Health Policy

Author:

Jäkel Anne,Plested Melanie,Dharamshi Kuntal,Modha Rakhee,Bridge Sarah,Johns Adam

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics and Econometrics,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40258-012-0001-1.pdf

Reference65 articles.

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [online]. http://globocan.iarc.fr/ . Accessed 2010 Nov 03.

2. Cancer Research UK. Lung cancer and smoking statistics: key facts [online]. http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/lung-cancer/ . Accessed 2010 Nov 05.

3. Cancer Research UK. UK cancer incidence statistics for common cancers [online]. http://info.cancerresearchuk.org/cancerstats/incidence/commoncancers/ . Accessed 2009 Feb 01.

4. Chouaid C, Atsou K, Hejblum G, et al. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics. 2009;27(2):113–25.

5. Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143–54.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MiR-3074-5p suppresses non-small cell lung cancer progression by targeting the YWHAZ/Hsp27 axis;International Immunopharmacology;2024-09

2. Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade;The European Journal of Health Economics;2024-08-30

3. Mir-3074-5p Suppresses Non-Small Cell Lung Cancer Progression by Targeting the Ywhaz/Hsp27 Axis;2024

4. Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-02-22

5. A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer;The European Journal of Health Economics;2019-03-06